Category: <span>Non-Small Cell Lung Cancer (NSCLC)</span>

Category: Non-Small Cell Lung Cancer (NSCLC)

Atezolizumab, clinicaltrials.gov, Director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, FDA Modernization Act of 1997, Founder of the Bonnie J. Addario Lung Cancer Foundation Bonnie Addario, Immunotherapy, M.D., malignant pleural mesothelioma, Mesothelioma News, Non-Small Cell Lung Cancer (NSCLC), PD-L1 inhibitor, Richard Pazdur, Tecentriq, U.S. Food and Drug Administration (FDA), U.S. National Institutes of Health (NIH)

Atezolizumab Approved for Non-Small Cell Lung Cancer Patients

 

PD-L1 inhibitor atezolizumab has been approved for use with chemotherapy-refractory metastatic Non-Small Cell Lung Cancer patients.

Atezolizumab, clinicaltrials.gov, Director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, FDA Modernization Act of 1997, Founder of the Bonnie J. Addario Lung Cancer Foundation Bonnie Addario, Immunotherapy, M.D., malignant pleural mesothelioma, Mesothelioma News, Non-Small Cell Lung Cancer (NSCLC), PD-L1 inhibitor, Richard Pazdur, Tecentriq, U.S. Food and Drug Administration (FDA), U.S. National Institutes of Health (NIH)

Atezolizumab Approved for Non-Small Cell Lung Cancer Patients

 

PD-L1 inhibitor atezolizumab has been approved for use with chemotherapy-refractory metastatic Non-Small Cell Lung Cancer patients.